|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Postcoital contraception: current use and future prospects. [La |
| contraception post-coitale: point actuel et perspectives.] |
| Bordeaux Medical 8(12): 1443-1456. 1975. |
| The current use of high doses of estrogens for single unprotected coitus in midcycle, and potential uses of |
| progestagens, estrogens, or pr ogestagens after each coitus, and other substances being considered, are reviewed. |
| The estrogens are prescribed for 5 days beginning within 24-72 hours after intercourse, or at the temperature shift: 5 |
| mg ethinyl estradiol, 50 mg diethyl stilbestrol, or 30 mg conjugated estrogens. Their mode of action is probably |
| central inhibition of luteal steroidogenesis by negative feedback of luteinizing hormone release, a mechanism called |
| ovum interception. Their efficacy is about .4%, a figure that must be considered in the context of a 2-4% risk of |
| pregnancy from any unprotected intercourse and 10% in the ovulatory phase. Side effects are nausea in 50%, |
| vomiting in 25%, and various complaints in 10% such as headache, then an irregular cycle in 33%. Ect opic |
| pregnancy is common, 10% in case of failure. The indication is single unprotected intercourse, e.g., cases of rape, |
| 1st act of intercourse or changing a contraceptive method. Some trials with progestagens used after each coitus, |
| e.g., .5-2 mg quinegestanol acetate or 150 or 400 mcg d-norgestrel, have not proved effective. Other possibilities not |
| found to be effective in women include PGEs and PGF2a, or not yet tried are antiestrogens, antiprogestagens, |
| inhibitors of steroidogenesis, ergot derivatives, inhibitors of implantation and pheromones. (PubHealth.info |
| Document ID: CONT7T 3084-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Postcoital contraception: current use and future prospects. |
| [La contraception post-coitale: point actuel et perspectives.]", is(are) Emperaire JC. The source of this article is |
| "Bordeaux Medical 8(12): 1443-1456. 1975.". This article was published in 1975 in French language(s). |
| (PubHealth.info® Document ID: CONT7T 3084-06. All rights reserved with PubHealth.info) PIN: 33084 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |